Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Role of Cytokines in Chemotherapy-related Cognitive Impairment of Breast Cancer Patients: A Systematic Review

Author(s): Kanika Tyagi, Md. Masoom, Haya Majid, Aakriti Garg, Dinesh Bhurani, Nidhi B. Agarwal and Mohd. Ashif Khan*

Volume 18, Issue 2, 2023

Published on: 10 May, 2022

Page: [110 - 119] Pages: 10

DOI: 10.2174/2772432817666220304212456

Price: $65

Abstract

Background: Cognitive impairment is one of the most common problems experienced by patients receiving chemotherapy, and evidence suggests that cytokines might play an important role. Various studies were conducted to evaluate the role of cytokines in chemotherapy-related cognitive impairment (CRCI). However, the association between CRCI due to cytokines is not well-established. Thus, this systematic review aims to assess the role of cytokines in CRCI in breast cancer patients.

Methods: This systematic review was conducted according to the Preferred Reporting Item for Systematic Review and Meta-analysis (PRISMA) guidelines. An intense literature search was carried out for inclusion criteria in major databases, including PubMed and Clinicaltrials.gov, in August 2021. Studies assessing cognitive parameters through objective and subjective assessment in breast cancer patients receiving chemotherapy were included.

Results: A total of 4052 studies were identified, and 15 studies were included in this systematic review. We found that IL-6, IL-1β, and TNF-α were associated with varying degrees of cognitive impairment in breast cancer patients receiving chemotherapy.

Conclusion: This systematic review showed a correlation between various cytokines and chemotherapy- associated cognitive decline in breast cancer patients.

Keywords: Breast cancer, chemotherapy, cytokines, cognition, CRCI, interleukins.

Next »
Graphical Abstract

[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Scherling CS, Smith A. Opening up the window into “chemobrain”: A neuroimaging review. Sensors 2013; 13(3): 3169-203.
[http://dx.doi.org/10.3390/s130303169] [PMID: 23467031]
[3]
Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review. Cancer Treat Rev 2012; 38(7): 926-34.
[http://dx.doi.org/10.1016/j.ctrv.2012.05.002] [PMID: 22658913]
[4]
Mehnert A, Scherwath A, Schirmer L, et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 2007; 66(1): 108-18.
[http://dx.doi.org/10.1016/j.pec.2006.11.005] [PMID: 17320337]
[5]
Vardy J, Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol 2007; 63(3): 183-202.
[http://dx.doi.org/10.1016/j.critrevonc.2007.06.001] [PMID: 17678745]
[6]
Janelsins MC, Mustian KM, Palesh OG, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer 2012; 20(4): 831-9.
[http://dx.doi.org/10.1007/s00520-011-1158-0] [PMID: 21533812]
[7]
Correa DD, Ahles TA. Neurocognitive changes in cancer survivors. Cancer J 2008; 14(6): 396-400.
[http://dx.doi.org/10.1097/PPO.0b013e31818d8769] [PMID: 19060604]
[8]
Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7(3): 211-7.
[http://dx.doi.org/10.1016/j.ccr.2005.02.013] [PMID: 15766659]
[9]
Jeong GH, Lee KH, Lee IR, et al. Incidence of capillary leak syndrome as an adverse effect of drugs in cancer patients: A systematic review and meta-analysis. J Clin Med 2019; 8(2): 8.
[http://dx.doi.org/10.3390/jcm8020143] [PMID: 30691103]
[10]
Keskin H, Cadirci K, Demirkazik A, et al. Following chemotherapy:Serum cytokine (tumor necrosis factor, interleukin-2, interleukin-11), immunoglobulin, complement, vascular endothelial growth factor levels, and the systemic symptoms like capillary leak syndrome. Biomark Cancer 2019; 11: 1179299X19854447.
[11]
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 2008; 9(1): 46-56.
[http://dx.doi.org/10.1038/nrn2297] [PMID: 18073775]
[12]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[13]
Jenkins V, Thwaites R, Cercignani M, et al. A feasibility study exploring the role of pre-operative assessment when examining the mechanism of ‘chemo-brain’ in breast cancer patients. Springerplus 2016; 5: 390.
[http://dx.doi.org/10.1186/s40064-016-2030-y] [PMID: 27047716]
[14]
Berlin JD, Feng Y, Catalano P, et al. An intergroup randomized phase II study of bevacizumab or cetuximab in combination with gemcitabine and in combination with chemoradiation in patients with resected pancreatic carcinoma: A trial of the ECOG-ACRIN cancer research group (E2204). Oncology 2018; 94(1): 39-46.
[http://dx.doi.org/10.1159/000480295] [PMID: 29040974]
[15]
Yap NY, Toh YL, Tan CJ, Acharya MM, Chan A. Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment. Cytokine 2021; 144: 155556.
[http://dx.doi.org/10.1016/j.cyto.2021.155556] [PMID: 33985854]
[16]
Chen VCH, Lin CK, Hsiao HP, et al. Effects of cancer, chemotherapy and cytokines on subjective and objective cognitive functioning among patients with breast cancer. Cancers 2021; 13(11): 13.
[http://dx.doi.org/10.3390/cancers13112576] [PMID: 34073990]
[17]
Zhao J, Zuo H, Ding K, et al. Changes in plasma IL-1β TNF-α and IL-4 levels are involved in chemotherapy-related cognitive impairment in early-stage breast cancer patients. Am J Transl Res 2020; 12: 3046-56.
[18]
Vardy JL, Stouten-Kemperman MM, Pond G, et al. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav 2019; 13(1): 15-26.
[http://dx.doi.org/10.1007/s11682-017-9728-5] [PMID: 28466438]
[19]
Henneghan AM, Palesh O, Harrison M, Kesler SR. Identifying cytokine predictors of cognitive functioning in breast cancer survivors up to 10 years post chemotherapy using machine learning. J Neuroimmunol 2018; 320: 38-47.
[http://dx.doi.org/10.1016/j.jneuroim.2018.04.012] [PMID: 29759139]
[20]
Lyon DE, Cohen R, Chen H, et al. Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer. J Neuroimmunol 2016; 301: 74-82.
[http://dx.doi.org/10.1016/j.jneuroim.2016.11.002] [PMID: 27890459]
[21]
Chae JW, Ng T, Yeo HL, et al. Impact of TNF-α (rs1800629) and IL-6 (rs1800795) polymorphisms on cognitive impairment in Asian breast cancer patients. PLoS One 2016; 11(10): e0164204.
[http://dx.doi.org/10.1371/journal.pone.0164204] [PMID: 27701469]
[22]
Cheung YT, Ng T, Shwe M, et al. Department of Pharmacy, National University of Singapore, Singapore Department of Pharmacy, National Cancer Centre Singapore, Singapore Department of Pharmacy, KK Women’s and Children’s Hospital, Singapore Breast Centre, KK Women’s and Childr. 2015.
[23]
Kesler S, Hadi Hosseini SM, Heckler C, et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer 2013; 13(4): 299-306.
[http://dx.doi.org/10.1016/j.clbc.2013.02.004] [PMID: 23647804]
[24]
Pomykala KL, Ganz PA, Bower JE, et al. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav 2013; 7(4): 511-23.
[http://dx.doi.org/10.1007/s11682-013-9243-2] [PMID: 23835929]
[25]
Ganz PA, Bower JE, Kwan L, et al. Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun 2013; 30 (Suppl.): S99-S108.
[http://dx.doi.org/10.1016/j.bbi.2012.07.015] [PMID: 22884417]
[26]
Booth CM, Vardy J, Crawley A, et al. Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. J Clin Oncol 2006; 24(18) (Suppl.): 8501.
[http://dx.doi.org/10.1200/jco.2006.24.18_suppl.8501]
[27]
Williams AM, Shah R, Shayne M, et al. Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy. J Neuroimmunol 2018; 314: 17-23.
[http://dx.doi.org/10.1016/j.jneuroim.2017.10.005] [PMID: 29128118]
[28]
Kotb MG, Soliman AER, Ibrahim RI, et al. Chemotherapy-induced cognitive impairment in hematological malignancies. Egypt J Neurol Psychiat Neurosurg 2019; 55: 56.
[http://dx.doi.org/10.1186/s41983-019-0104-9]
[29]
Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58(5): 445-52.
[http://dx.doi.org/10.1001/archpsyc.58.5.445]
[30]
Vodermaier A. Breast cancer treatment and cognitive function: The current state of evidence, underlying mechanisms and potential treatments. Womens Health 2009; 5(5): 503-16.
[http://dx.doi.org/10.2217/WHE.09.36] [PMID: 19702450]
[31]
Jung MS, Zhang M, Askren MK, et al. Cognitive dysfunction and symptom burden in women treated for breast cancer: A prospective behavioral and fMRI analysis. Brain Imaging Behav 2017; 11(1): 86-97.
[http://dx.doi.org/10.1007/s11682-016-9507-8] [PMID: 26809289]
[32]
Sousa H, Almeida S, Bessa J, Pereira MG. The developmental trajectory of cancer-related cognitive impairment in breast cancer patients: A systematic review of longitudinal neuroimaging studies. Neuropsychol Rev 2020; 30(3): 287-309.
[http://dx.doi.org/10.1007/s11065-020-09441-9] [PMID: 32607817]
[33]
Donzis EJ, Tronson NC. Modulation of learning and memory by cytokines: signaling mechanisms and long term consequences. Neurobiol Learn Mem 2014; 115: 68-77.
[http://dx.doi.org/10.1016/j.nlm.2014.08.008] [PMID: 25151944]
[34]
Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 2012; 8(9): 1254-66.
[http://dx.doi.org/10.7150/ijbs.4679] [PMID: 23136554]
[35]
Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995; 2(4): 241-8.
[http://dx.doi.org/10.1159/000097202] [PMID: 8963753]
[36]
Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009; 73(10): 768-74.
[http://dx.doi.org/10.1212/WNL.0b013e3181b6bb95] [PMID: 19738171]
[37]
Sudheimer KD, O’hara R, Spiegel D, et al. Cortisol, cytokines, and hippocampal volume interactions in the elderly 2014.
[http://dx.doi.org/10.3389/fnagi.2014.00153]

Rights & Permissions Print Cite
Article Metrics
56
2
© 2024 Bentham Science Publishers | Privacy Policy